Evidence map›Paper›PMID 39502489›Full record

ReviewDigital health

Considerations for regulation and evaluation of digital mental health technologies.

Gareth Hopkin, Richard Branson, Paul Campbell, Holly Coole, Sophie Cooper, Francesca Edelmann, Mark Salmon

Abstract readReview
In one paragraph

Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gareth HopkinScience Evidence and Analytics Directorate, National Institute for Health and Care Excellence (NICE), Manchester, England, UK.ORCID https://orcid.org/0000-0002-6860-7277
Richard BransonSoftware Team, Healthcare Quality and Access Group, Medicines and Healthcare products Regulatory Agency, London, England, UK.
Paul CampbellSoftware Team, Healthcare Quality and Access Group, Medicines and Healthcare products Regulatory Agency, London, England, UK.
Holly CooleSoftware Team, Healthcare Quality and Access Group, Medicines and Healthcare products Regulatory Agency, London, England, UK.
Sophie CooperScience Evidence and Analytics Directorate, National Institute for Health and Care Excellence (NICE), Manchester, England, UK.
Francesca EdelmannSoftware Team, Healthcare Quality and Access Group, Medicines and Healthcare products Regulatory Agency, London, England, UK.
Mark SalmonScience Evidence and Analytics Directorate, National Institute for Health and Care Excellence (NICE), Manchester, England, UK.ORCID https://orcid.org/0000-0002-7909-3769

Funding

Wellcome Trust
6 · The paper itself

Abstract

Digital mental health technologies (DMHTs) are becoming well established within mental health services and through direct-to-consumer models. Due to their scalable nature, DMHTs may support services to bridge the gap between demand and the available workforce, particularly where existing pathways have long delays or restricted capacity. Challenges and risks associated with DMHTs also need consideration. Regulatory and health technology assessment (HTA) agencies play a key role in ensuring the potential of DMHTs is achieved and their risks are mitigated. However, the nature of DMHTs and advances in digital technology present challenges for regulation and evaluation. In this paper, we describe eight key considerations across the regulatory and HTA pathway for DMHTs. These relate to 1) intended purpose, 2) qualification and classification, 3) risk management, 4) clinical evidence, 5) resource requirements and economic evidence, 6) post-market surveillance and life cycle assessment, 7) replicability and equity, and 8) wider responsibilities. Ensuring clarity within these considerations and addressing outstanding uncertainties is necessary to ensure that the benefits of DMHTs are unlocked, while also ensuring that people have access to high quality and safe tools.

Indexed as

evaluationhealth technology assessmentregulationSaMDsoftware as a medical device

Identifiers

PMID39502489
PMCPMC11536580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.